Home › NDC Lookup › RxCUI directory › RxCUI 2361290

Tucatinib 150 MG Oral Tablet — RxCUI 2361290

RxNorm drug concept · Semantic clinical drug
RxCUI 2361290 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2361290
Official nameTucatinib 150 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)795 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tucatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tukysa targets a protein called HER2 that is overactive in your cancer and tells cells to keep growing uncontrollably. By blocking HER2, it helps slow or stop tumor growth. It's al...
  • What exactly does Tukysa do, and why do I need to take it with other drugs?
  • Diarrhea is very common with Tukysa, and it can be serious if not managed quickly. Most people experience it within the first two weeks of treatment. You should start anti-diarrhea...
  • Diarrhea sounds like a common side effect — how bad can it get, and what should I do?
📖 Read our full Tucatinib guide →

🕸️ Concept Web — How Tucatinib 150 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tucatinib 150 MG Oral Tablet RxCUI 2361290

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tucatinib 2361285
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tukysa 2361291
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tucatinib Oral Tablet 2361289
    • Tucatinib Oral Product 2361287
    • Tucatinib Pill 2361288
    • Tucatinib Oral Tablet [Tukysa] 2361293
    • Tukysa Oral Product 2361294
    • Tukysa Pill 2361295
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tucatinib 150 MG SCDC · 2361286
  • Tucatinib Oral Tablet SCDF · 2361289
  • Tucatinib Oral Product SCDG · 2361287
  • Tucatinib Pill SCDG · 2361288

Brand-Name Concepts

  • Tucatinib 150 MG Oral Tablet [Tukysa] SBD · 2361296
  • Tucatinib 150 MG [Tukysa] SBDC · 2361292
  • Tucatinib Oral Tablet [Tukysa] SBDF · 2361293
  • Tukysa Oral Product SBDG · 2361294
  • Tukysa Pill SBDG · 2361295
  • Tukysa BN · 2361291

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 2361290 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
51144-0001-60 60 TABLET in 1 BOTTLE (51144-001-60) TUKYSA SEAGEN INC. 2020-04-17
51144-0002-12 120 TABLET in 1 BOTTLE (51144-002-12) TUKYSA SEAGEN INC. 2020-04-17
51144-0002-60 60 TABLET in 1 BOTTLE (51144-002-60) TUKYSA SEAGEN INC. 2020-04-17
Observed labelers: SEAGEN INC. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.